See the Complete Picture.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eid
Elon Musk
Donald Trump
World Cup
Artificial Intelligence
Social Media
Tesla
Housing
NBA
Education
Nintendo
Soccer
Published • loading... • Updated

Pepgen discontinues development of Duchenne MD exon-skipping therapy

Summary by Muscular Dystrophy News
Pepgen will stop development of its Duchenne MD exon-skipping therapy PGN-ED051 after increases in dystrophin levels proved disappointing.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Muscular Dystrophy NewsMuscular Dystrophy News

Pepgen discontinues development of Duchenne MD exon-skipping therapy

Pepgen will stop development of its Duchenne MD exon-skipping therapy PGN-ED051 after increases in dystrophin levels proved disappointing.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Muscular Dystrophy News broke the news in on Tuesday, June 3, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Mississippi

Mississippi

News
For You
SearchBlindspotLocal